enGene Therapeutics Inc. ENGN
NASDAQ
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -7.52% | -1.60% | 21.46% | -30.66% | -12.30% |
| Total Depreciation and Amortization | -1.11% | -4.76% | 10.53% | 31.54% | 22.64% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 91.47% | 29.71% | 22.01% | 21.29% | 33.97% |
| Change in Net Operating Assets | 218.18% | -81.21% | -125.06% | 849.91% | -7.22% |
| Cash from Operations | 37.88% | -5.52% | -15.79% | 2.62% | -11.71% |
| Capital Expenditure | 100.00% | 35.95% | 64.99% | 37.93% | -1,464.44% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 26.90% | 118.82% | -408.14% | 1,865.29% | -88.42% |
| Cash from Investing | 27.43% | 118.72% | -411.84% | 2,836.91% | -92.32% |
| Total Debt Issued | -- | -100.00% | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | -- | 100.00% | -- |
| Issuance of Common Stock | 475.00% | -100.00% | 7,422.65% | 6,121.88% | -83.92% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.00% | 100.70% | -- | -- | -- |
| Cash from Financing | -68.92% | -99.95% | 7,015.02% | 398.50% | -435.18% |
| Foreign Exchange rate Adjustments | -- | -100.00% | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 265.02% | 49.88% | -177.24% | 170.34% | -419.10% |